Oxidized LDL and paraoxanase status in ischemic stroke patients

Indian Journal of Physiology and Pharmacology

Volumn 52, Issue 4, 2008, Pages 403-407

  Dey Sarkar, Purnima ^a   Rautaray, Sushree S ^a,b  

^a MGM MEDICAL COLLEGE   (India)

^b NONE   (India)

Author keywords

Ischemic stroke; Ox ldl; Paraoxanase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; OXIDATIVE STRESS; SYSTOLIC BLOOD PRESSURE; ULTRACENTRIFUGATION;

AGED; ARYLDIALKYLPHOSPHATASE; BRAIN ISCHEMIA; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; STROKE;

EID: 67650538628     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Aviram M, Rosenblat M, Etzoini A, et. al. Activation of NADPH oxidase required for (macrophage mediated oxidation of low density lipoprotein. Metabolism 1996; 45: 1069-1079.
2. Ehara S, Naruko T, et. al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 1955-1960.
3. Gan KN, Smolen A, Eckerson HW. Purification of human serum paraoxanase/ arylesterase. Evidence for one esterases catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
4. Itabe H, Imanaka T, et. al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37: 45-53.
5. Itabe H, Takeshima E, Iwasaki H, et. al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994; 269: 15274-15279.
6. Itabe H, Suzuki M, et. al. Oxidised phosphatidyl-cholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 1996; 271: 33208-332117.
7. Kaplan M, Aviram M. Oxidised low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxanase. Clin Chem Lab Med 1999; 37: 777-787.
8. Mackness MI, Durrington NP. Human serum paraoxanase. Gen Pharmacol 1998; 31: 329-336.
9. Mackness MI, Mackness B, Durrington PN. Paraoxanase and coronary heart disease. Atheroscler Suppl 2002; 3: 49-55.
10. Murray CJ, Lopez AD. Mortality by cause for eight regions in the world: Global burden of disease study. Lancet 1997; 349: 1269-1276.
11. Murray CJ, Lpoez AD. Global mortality, disability, and the contribution of risk factors: global Burden of Disease Study. Lancet 1997; 349: 1436-1442.
12. Nishi K, Itabe H, et. al. Oxidised ldl in carotid plaques and plasma associates with plaque instability. Arterioscl Thromb Vase Biol 2002; 22: 1649-1654.
13. Polidori MC, Cherubini A, et. al. Increased plasma levels of hydroperoxides in patients with ischemic stroke. Free Radic Biol Med 1998; 25: 561-567.
14. Rajagopalan S, Mehta RH, et. al. Effect of Losartan in ageing related endothelial impairment. Am J Cardiol 2002; 89: 562-566.
15. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
16. Sun D, Gilobe DD. Ischemia induced changes in cerebral mitochondrial free fatty acids, phospholipids, and respiration in the rat. J Neurochem 1994; 62: 1921-1928.
17. Taddei S, Virdis A, et. al. Age related reduction of NO availability and oxidative stress in humans. Hypertension 2001; 38: 274-279.
18. Toshima S, Hasegawa A, et. al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vase Biol 2000; 22: 2243-2247.